Preparing Early for a Successful FDA Advisory Committee or Device Panel Meeting

May 18, 2016

Given the Food and Drug Administration’s (FDA) increased scrutiny of clinical and long‐term safety, the agency is calling for more public Advisory Committee hearings each year. Good data alone are no longer enough to win approval. In today’s environment, it is critical to prepare a clear, credible and engaging presentation and to start the preparation process early. You must ensure that your team is ready for the most difficult questions in order to sustain credibility and achieve a positive committee recommendation. Importantly, Sponsors need to understand the FDA’s guidance on panel review meetings and their implications so that they can anticipate likely panel questions well before NDA or PMA submission. In doing so, Sponsors can proactively engage with FDA early and consistently throughout the product development program. Most companies are ill‐equipped to prepare for a daunting FDA Advisory Committee or Device Panel meeting. With so much at risk in a single presentation, all stakeholders must mobilize and have a clear strategy when approaching FDA for market approval. This presentation will walk you through key aspects of FDA’s guidance and provide you with proven steps that will optimize your success before an FDA Advisory Committee meeting.

Learning Objectives:

Upon the presentation’s conclusion, you should be able to:

Understand the process leading up to an Advisory Committee or Device Panel meeting, for both the Sponsor and FDA

Understand all the essential steps necessary to be successful at an FDA Advisory Committee meeting

Identify key project activities that can be strengthened by incorporation of panel considerations

Staff a team of internal personnel and external advisors to properly prepare for an FDA Advisory Committee meeting

Strategize opportunities for improving the chances of success

Download Slide Notes

Growing the Choir: More Voices Joining the Healthcare Value Conversation – Part 1

December 18, 2018

This year I was struck by a new vibe at ISPOR –the ‘must attend” conference for health economics outcomes research. ISPOR aspired to — and succeeded at — broadening its reach by replacing its usual highly technical agenda, with one that was extremely relevant for these times. For the first…

WHAT THE THAI CAVE RESCUE TEACHES US ABOUT TEAMWORK

October 17, 2018

This summer’s dramatic rescue of 12 young soccer players and their coach from a flooded cave more than a mile deep into the earth is a lesson not only in the power of the human spirit but one that also can be applied to everyday business. On a personal level,…

Whether you are a CEO trying to strike a deal with an important client in a foreign country, or a team member trying to get something accomplished in your own office, cultural differences in communication often present major challenges.

There are many stakeholder groups that ultimately define the benefit-risk assessment of a medical device. These include payers, patient groups, providers, policy-makers, regulators, and many more. Benefit-risk messages touch on multiple points in the product life cycle and sponsors must constantly assess if the benefits outweigh the risks. The framework…

This website uses cookies to provide you with an improved and personalized experience. By using this site you agree to our use of cookies. Please read our cookies policy for more information on the cookies we use and how to delete or block them.